This was an open-labelled, comparative parallel-group study in the management of Asrigdara. In this trial total of 38 patients were enrolled, 34 patients completed the treatment, and follow-up, 4 patients were dropped out. In Group A 17 patients had been prescribed Virechana and Vasadi Churna 3 gm 6 hourly during bleeding and 3gm BD after bleeding and in Group B, 17 patients had been prescribed the Vasadi Churna 3gm 6 hourly during bleeding and 3gm BD after bleeding for 60 days. After the completion of the treatment protocol, the follow-up period was 1 month for both groups to assess the difference in the consecutive menstrual cycle. The assessment was done based on signs and symptoms i.e., Excessive Bleeding, Prolonged duration bleeding, Intermenstrual Bleeding, Bleeding with clots and associated complaints like Vedana, Angamarda, Panduta, Daurbalya, Daha, Bhrama. 

Results: In the Overall effect of therapy, percentage relief in Group A was 89.30% while in Group B it was 74.93%. In Group A 47.05% of patients got complete remission and 35.30% of patients were found to marked improvement. While 17.65% were found to moderate improvement, no patient was found Mild improvement and remained unchanged. In Group B 5.88% of patients got complete remission and 41.17% of patients found marked improvement. While 47.05% of patients got moderate improvement, 5.88% got Mild improvement and no patient remained unchanged. This data shows that Virechana with Vasadi Churna Group (Group A) is better than Vasadi Churna Group (Group B).

           So, analysing the data obtained from the present study, the null hypothesis i.e., Virechana followed by Vasadi Churna is not effective than that of Vasadi Churna alone in the management of Asrigdara (AUB)) has rejected and the alternate hypothesis i.e., Virechana followed by Vasadi Churna (Group A) is more effective than Vasadi Churna alone (Group B) in the management of Asrigdara (AUB)) has accepted.